(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 October 2025 (16.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/217521 A1

(51) International Patent Classification:
A61P 13/12 (2006.01) *A61P 1/16* (2006.01)
C07D 401/00 (2006.01) *A61K 31/395* (2006.01)
C07D 403/00 (2006.01) *A61K 31/33* (2006.01)
C07D 413/00 (2006.01) *A61P 3/00* (2006.01)

(21) International Application Number:
PCT/US2025/024284

(22) International Filing Date:
11 April 2025 (11.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/633,423 12 April 2024 (12.04.2024) US

(71) Applicant: **JNANA THERAPEUTICS INC.** [US/US]; One Design Center Place, Suite 19-400, Boston, MA 02210 (US).

(72) Inventors: **VRATSANOS, George**; 264 Castle Drive, Englewood Cliffs, NJ 07024 (US). **VIADER, Andreu**; 504 Essex St, Hamilton, MA 01982 (US). **WOBST, Heike, Julia**; 8 9th St., Apartment 803, Medford, MA 02155 (US). **BROWN, Dean, G.**; 10 Williams Way, Hollis, NH 03049 (US).


(74) Agent: **GORDON, Dana, M.** et al.; Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: TREATING CHRONIC KIDNEY DISEASE WITH A COMBINATION OF A SLC6A19 INHIBITOR AND A GLP-1 AGONIST

FIG. 1



(57) Abstract: Disclosed are methods for treating or preventing a disease or disorder selected from type 1 or type 2 diabetes mellitus, obesity, nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetic nephropathy, glomerulosclerosis, glaucoma, Alport Syndrome, Pyruvate Dehydrogenase Complex Deficiency (PDCD), and chronic kidney disease, comprising co-administering to a patient in need thereof an effective amount of a SLC6A19 inhibitor and an effective amount of a second agent, wherein the second agent is a GLP-1 receptor agonist, GIP agonist, or dual GLP-1 /GIP agonist

[Continued on next page]

WO 2025/217521 A1

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*